Fierce Biotech6d
J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
Narrow-Moat Genmab Benefits From Strong Demand for Darzalex as Pipeline Makes Progress
We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...
pharmaphorum5d
J&J abandons work with Genmab on Darzalex successor
A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...
China’s biotech is redrawing the global pharma map; what India can learn
American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...
Yahoo Finance5d
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
The company held an investor call to discuss the decision, during which it shared initial data from a head-to-head study comparing GEN3014 to Darzalex. While the results suggested potentially deeper ...